ArticleFrontiers in oncology2025
Elevated serum apelin levels in breast cancer patients: A potential biomarker with limited histopathological correlations.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Apelin, a peptide implicated in various physiological processes, has been shown to be involved in cancer development and progression. However, its role in breast cancer remains unclear. This study aimed to investigate serum apelin levels in breast cancer patients and explore potential associations with clinicopathological features. Methods: This study involved 137 histopathologically-confirmed female breast cancer patients and 71 healthy controls. Serum apelin levels were measured using enzyme-linked immunosorbent assay (ELISA) and patients' clinicopathological data was collected retrospectively. Serum apelin levels were compared between the patients and control groups. Moreover, Youden's J index and the receiver operating characteristic (ROC) curve analysis were utilized to select the optimal cut-off point to differentiate patients and healthy controls. A generalized linear model (GLM) was used to investigate the association of each histopathological variable with serum apelin levels. Results: Serum apelin levels were significantly higher in breast cancer patients (343.61 ± 182.69 pg/mL) compared to healthy controls (67.37 ± 30.18 pg/mL, p<0.001). ROC curve analysis revealed excellent discriminative ability of serum apelin in distinguishing breast cancer patients from healthy controls (AUC = 0.94, 95% CI: 0.91-0.98). The optimal cut-off value for serum apelin was determined to be 122.48 pg/mL, yielding 89% sensitivity and 97% specificity. However, GLM analysis found no statistically significant associations between serum apelin levels and clinicopathological features, including age, tumor size, histologic grade, lymphovascular invasion, lymph node involvement, microcalcification, Conclusions: Our findings suggest a potential role for serum apelin in breast cancer pathogenesis or progression. The high discriminative ability of serum apelin indicates its promise as a biomarker for breast cancer detection. However, the lack of association between serum apelin levels and specific clinicopathological features suggests a limited prognostic value and a complex role in breast cancer biology that warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.